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Iodinated contrast induced renal vasoconstriction
is due in part to the downregulation of renal
cortical and medullary nitric oxide synthesis
Stuart I. Myers, MD, Li Wang, BS, Fang Liu, BS, and Lori L. Bartula, BS, Richmond, Va
Objectives: The loss of renal function continues to be a frequent complication of the iodinated contrast agents used to
perform diagnostic angiography and endovascular procedures. This study examined the hypothesis that contrast-induced
renal injury is partly due to a decrease in cortical and medullary microvascular blood flow after the downregulation of
endogenous renal cortical and medullary nitric oxide (NO) synthesis.
Methods:Anesthetizedmale Sprague-Dawley rats (300 g) hadmicrodialysis probes or laser Doppler fibers inserted into the
renal cortex to a depth of 2 mm and into the renal medulla to a depth of 4 mm. Laser Doppler blood flow was
continuously monitored, and the microdialysis probes were connected to a syringe pump and perfused in vivo at 3
L/min with lactated Ringer’s solution. Dialysate fluid was collected at time zero (basal) and 60 minutes after infusion
of either saline or Conray 400 (6 mL/kg). Both groups were treated with saline carrier, N-nitro-L-arginine methyl ester
hydrochloride (L-NAME, 30 mg/kg), L-arginine (400 mg/kg), or superoxide dismutase (10,000 U/kg), an oxygen-
derived free radical scavenger. Dialysate was analyzed for total NO and eicosanoid synthesis. The renal cortex andmedulla
were analyzed for inducible NO synthase (iNOS), cyclooxygenase-2 (COX2), prostacyclin synthase, and prostaglandin E2
(PGE2) synthase content by Western blot analysis.
Results:Conray caused amarked decrease in cortical andmedullary blood flowwith a concomitant decrease in endogenous
cortical NO, PGE2, and medullary NO synthesis. The addition of L-NAME to the Conray further decreased cortical and
medullary blood flow and NO synthesis, which were restored toward control by L-arginine. Neither L-NAME nor
L-arginine (added to the Conray) altered cortical or medullary eicosanoids release. Medullary PGE2 synthesis decreased
when superoxide dismutase was added to the Conray treatment, suggesting that oxygen-derived free radicals had a
protective role in maintaining endogenous medullary PGE2 synthesis after Conray treatment. Conray did not signifi-
cantly alter iNOS, COX-2, prostacyclin synthase, or PGE2 synthase content.
Conclusions: These findings suggest that the downregulation of renal cortical and medullary NO synthesis contributes to the
contrast-induced loss of renal cortical and medullary microvascular blood flow. Preservation of normal levels of renal cortical
and medullary NO synthesis may help prevent or lessen contrast-induced renal vasoconstriction and lessen contrast-induced
renal injury found after diagnostic and therapeutic endovascular procedures. (J Vasc Surg 2006;44:383-91.)
Clinical Relevance: This study suggests that clinically relevant cortical and medullary vasodilators (NO and vasodilator
prostanoids) are required to maintain microvascular renal cortical and medullary blood flow. This study combines in vivo
techniques of microdialysis and laser Doppler flow probes to show that endogenous NO synthesis is important in serving
a protective role to prevent vasoconstriction at the local cortical and medullary levels after radiocontrast administration.
Understanding the mechanisms of contrast-induced nephropathy will help develop treatment regimens to either
minimize or eliminate this important complication of contrast agents.The administration of contrast media continues to be a
frequent cause of hospital-acquired renal failure.1 Over the
past few years, the increasing numbers of diagnostic and
interventional procedures requiring contrast media has par-
alleled an increasing incidence of contrast media-induced
nephropathy. Contrast media-induced nephropathy now
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doi:10.1016/j.jvs.2006.04.036accounts for 10% of hospital-acquired renal failure and
has the third leading cause of iatrogenic acute renal failure
in hospitalized patients.1-7 The increased incidence of con-
trast media-induced nephropathy is associated with an in-
crease in hospital mortality, length of stay, and hospital
costs.8-10
One of the difficulties in treating or preventing renal
failure after contrast media administration is that the bio-
chemical mechanisms of contrast media-induced nephrop-
athy have not been identified. One group of studies has
hypothesized that nitric oxide (NO) contributes to preserv-
ing renal blood flow and function in normal and pathologic
states. As a result of these studies, several authors investi-
gated the potential role of NO in contrast media-induced
nephropathy. Several authors have shown that NO inhibi-
tion before radiocontrast administration results in the abo-
lition of the medullary vasodilatory response and contrib-
utes to regional hypoxic renal tubular injury.11-14 Heyman
et al13 also suggested that maintenance of local vasodilatory
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important in maintaining regional blood flow to the me-
dulla. These studies have provided insight into the impor-
tance of endogenous renal NO and PGE2 in the pathogen-
esis of contrast media-induced nephropathy; however, they
have not identified the specific site of radiocontrast-
induced inhibition of these important endogenous renal
vasodilators.
We recently combined the use of in vivo microdialysis
and laser Doppler blood flow analyses to identify clinically
relevant intrarenal vasodilators (cortical and medullary)
that are required tomaintain microvascular blood flow after
distant injury.15,16 We have adapted our experimental de-
sign to further define the role and location of endogenous
renal vasodilators in the pathogenesis of contrast media-
induced nephropathy. This study examined the hypothesis
that contrast media-induced nephropathy is partly due to
concomitant decreases in renal cortical and medullary NO
synthesis and blood flow.
MATERIALS AND METHODS
Animal model. All animal surgery and care was per-
formed using the established guidelines approved by the
Institutional Animal Care and Use Committee (IACUC),
Virginia Commonwealth University/Medical College of
Virginia, and the McGuire VAMedical Center, Richmond,
Virginia. Male Sprague-Dawley rats (Harlan, Indianapolis,
Ind) weighing about 350 g were anesthetized with 2%
isoflurane vaporized by oxygen and underwent a laparot-
omy using sterile technique.15,16 The rats were placed on a
small-animal operating table with a fixed bar clamp holding
a Lucite kidney cup for isolation of the kidney from move-
ment. This allowed for precise placement of cortical and
medullary laser fiber probes with micropositioners. Micro-
dialysis catheters were also placed through the renal cortex
and medulla in separate groups.
The right femoral artery was cannulated, heparinized
(100U/kg), and connected to a blood pressure analyzer
(Digimed, Louisville, Ky) for constant monitoring of heart
rate and arterial blood pressure. Perivascular ultrasonic
blood flow probes (Transonic Systems, Inc, Ithaca, NY)
were placed around the renal artery and the abdominal
aorta, and data were collected as milliliters per minute.
Body temperature was monitored with a rectal temperature
probe. The animal’s abdomen was filled with saline and
lubricating jelly to insulate contact between blood flow
probes and blood vessels. Microdialysis probes or laser
Doppler fibers were inserted into the renal cortex to a depth
of 2 mm and into the renal medulla to a depth of 4 mm (see
next section for details).15,16
Both the laser Doppler blood flow and microdialysis
groups were treated with saline carrier, 30 mg/kg N-
nitro-L-arginine methyl ester hydrochloride (L-NAME), a
NO synthase (NOS) inhibitor; 400 mg/kg L-arginine, a
NO precursor; or 10,000 U/kg superoxide dismutase
(SOD), an oxygen-derived free radical scavenger.17,18 All
drugs were given intravenously, 30 minutes before Conray
400 (Mallinkrodt Inc, Hazelwood, Mo) administration.Conray 400 (6 mL/kg) was given as intra-arterial in-
jections to mimic the clinical use of contrast agents because
it is used at this concentration as a standard in the medical
literature.11-14 After the experiment, the renal cortex and
medulla were separated and analyzed for inducible NOS
(iNOS), cyclooxygenase 2 (COX-2), prostacyclin synthase,
and PGE2 synthase content by Western blot.
Microdialysis probes in vivo perfusion. Microdialysis
probes were prepared as previously described.15,16,19-21
One microdialysis probe was inserted into the renal cortex
to a depth of 2 mm and another into the renal medulla at 4
mm. These probes were connected to a syringe pump and
perfused at a rate of 3 L/min with lactated Ringer’s
solution. Dialysate fluid was collected at basal time zero and
60 minutes after the intravenous administration of Conray
400 (6 mL/kg) and compared with saline control. Dialy-
sate samples were collected and frozen at –80°C until
assayed for total NO (M), PGE2, 6-keto-PGF1 (PGI2
metabolite), and thromboxane B2 (TxB2, thromboxane A2
metabolite) synthesis. Data are reported as percent change
of each substance after the Conray treatment compared
with the baseline time zero.
Use of the microdialysis probes allowed NO, PGE2,
6-keto-PGF1 and thromboxane B2 to diffuse in and out of
the dialysis probe, depending on the local concentration.
Because NO and the eicosanoids measured are not stored
within the cell, release of these substances represent de
novo synthesis. After completion of each experiment, the
kidneys were opened to confirm accurate placement of the
microdialysis probes.16
Laser Doppler renal cortical and medullary blood
flow analysis. The right kidney was isolated and placed in
a 21-mm Lucite kidney cup. Ultrasonic blood flow probes
(Transonic Systems, Inc, Ithaca, NY) were placed around
the renal artery and abdominal aorta, and data were col-
lected as milliliters per minute. Body temperature was
monitored with a rectal probe. Micropositioners were used
to insert the shallow (2-mm cortical) and deep (4-mm
medullary) calibrated laser fiber probes. Position of the
fibers within the kidneys was checked after each experi-
ment. A Periflux 4001 Dual Channel Laser Doppler flow-
meter (Perimed, Järfälla, Sweden) was used to evaluate
microvascular perfusion. Measurements were expressed as
arbitrary perfusion units that represent the product of the
velocity and the concentration of moving blood cells within
the measuring volume. After 5 minutes of equilibration,
basal readings were recorded and subsequent readings were
recorded every 10 minutes throughout the experi-
ment.15,16,22,23 Data are reported as percent change of
cortical or medullary blood flow 60 minutes after the
Conray administration.
Enzyme immunoassays. The renal microdialysis ef-
fluent was frozen at –80°C until assayed for PGE2, 6-keto-
PGF1, and thromboxane B2 by an enzyme immunoassay
kit (Cayman Chemical, Ann Arbor, Mich).24 Samples were
run in duplicate and reported as picograms of eicosanoid
measured per milliliter (mean SEM). Data were reported
as percent change compared with baseline at time zero.15,16
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Analyzer with Radical Purger (Sievers Instruments, Boul-
der, Colo) was used to detect NO (M) and its reaction
products in biologic samples. The technique used for the
measurement of NO and its oxidation products was the
reduction of nitrate, nitrite, and nitrosothiol using vana-
dium (III) and hydrochloric acid at 90°C.15,16 The data are
reported as percent change compared with baseline time
zero.
Protein assays. The kidneys were harvested and
placed on ice. Cortical and medullary tissues were rapidly
separated as previously described.15,16,24 The tissues were
then frozen in liquid nitrogen and stored at –80°C until
assayed for protein. Tissues were thawed in a phosphate
buffer, homogenized, and centrifuged at 4°C for 20 min-
utes. Supernatants were decanted, and total protein was
determined by the Bradford method25 using a protein assay
dye reagent concentrate (Bio-Rad Laboratories, Hercules,
Calif). A 5X sodium dodecylsulfate (SDS) sample buffer
(1X  62.5 mM Tris-HCl, pH 8.0; 2% SDS; 0.025%
bromophenol blue; 20% glycerol; 5% -mercaptoethanol)
was added to the protein samples and stored at –80°C until
assayed by Western blot.
Sodium dodecyl sulfate polyacrylamide gel electro-
phoresis/Western blot analyses. Protein samples diluted
in SDS sample buffer were solubilized by boiling for 4
minutes. Aliquots (25 g) were loaded into gel lanes of a
vertical electrophoretic unit (Bio-Rad), and protein separa-
tion by molecular weight was done on 1 mm 7% polyacryl-
amide resolving gel with a 1-mm 3% stacking gel by the
Laemmli method,26 which includes prestained molecular
weight standard markers (Sigma, St Louis, Mo). Proteins
were then transferred from the resolving gels to nitrocellu-
lose membranes (Schleicher & Schuell, Keene, NH), as
described by Burnette,27 by using a Trans-Blot electro-
phoretic transfer cell (Bio-Rad) operating at 100 mA for 18
hours at 4°C.
The membranes were incubated for 1 hour at room
temperature in blocking buffer (buffer B: 10 mM sodium
phosphate, 0.5 M sodium chloride, 10% bovine serum
albumin, 0.05% Tween 20) and subsequently overnight at
room temperature in buffer B containing a primary anti-
body24,28 -cyclooxygenase-2 polyclonal antiserum (Cay-
man Chemical Co, Ann Arbor, Mich), PGE2 synthase
(Cayman Chemical Co), prostacyclin synthase (-prostacy-
clin synthase polyclonal antiserum donated by Dr William
Smith, Michigan State University, East Lansing), or -
inducible NOS antiserum (Oxford Biomedical Research,
Inc, Oxford, Mich). The nitrocellulose membranes were
then washed of excess primary antibody at room tempera-
ture in phosphate-buffered saline Tween buffer (PBST: 10
mM potassium phosphate, pH 7.4, 0.9% sodium chloride,
0.05% Tween 20) and incubated for 1 hour at room tem-
perature in buffer B and secondary antibody, goat -rabbit
immunoglobulin G horseradish peroxidase (Bio-Rad).
The membranes were washed of secondary antibody at
room temperature in PBST, incubated in chemilumines-
cence reagent (Renaissance, DuPont-NEN, Boston, Mass)for 1minute, inserted into a plastic sheet protector, bubbles
removed, and placed against autoradiography film (Kodak,
Rochester, NY). The film exposure times were adjusted to
obtain the ideal density of bands identifying the enzymes of
interest and an imaging system (Alpha Innotech, San Le-
andro, Calif) was used to measure these bands by spot
densitometry.
Creatinine clearance. Serum creatinine, urine creati-
nine and urine volume were measured in a separate groups
of animals.15,16 These groups underwent the same treat-
ment with saline control or intravenous Conray 400 (6
mL/kg) but without placement of microdialysis probes or
laser Doppler fibers in the kidneys. Serum and urinary
creatinine were measured by a SYNCHRON LC System
(BeckmanCoulter, Inc, Fullerton, Calif). Data are reported
as milliliters per minute (mean  SEM).
Statistical analysis. The NO and eicosanoid release
data and the laser blood flow data are converted to percent
of original basal time to control for any intra-experiment
variation. Western blot data are expressed as densitometry
units, and the creatinine clearance is expressed as milliliters
per minute. The heart rate is expressed as beats per minute,
and the blood pressure is reported as mean blood pressure
in mm Hg. All data are expressed as mean SEM. An n
6 is used for all groups. Analysis of variance and Student’s t
tests were used to determine differences among the groups.
P  .05 was considered statistically significant.
RESULTS
Treatment with Conray did not significantly alter mean
blood pressure compared with the sham group. As ex-
pected, L-NAME increased blood pressure but was not
altered by treatment with SOD or L-arginine (Fig 1, A).
Conray did not alter heart rate compared with the sham
group. Treatment of the Conray or sham groups with
carrier, SOD, L-NAME, or L-arginine, did not alter heart
rate as well (Fig 1, B).
Conray treatment decreased renal cortical and medul-
lary blood flow compared with the saline group (Figs 2 and
3). Pretreatment of the animals with SOD before Conray
administration did not alter the decrease in cortical blood
flow but did further decrease medullary blood flow com-
pared with group treated only with Conray, suggesting that
oxygen-derived free radicals did not contribute to the
Conray-induced decrease in cortical and medullary blood
flow (Figs 2 and 3). Treatment of the animals with L-
NAME before Conray administration profoundly de-
creased cortical and medullary blood flow, whereas L-
arginine pretreatment reversed the fall in blood flow after
Conray treatment (Figs 2 and 3).
NO release was markedly decreased after Conray treat-
ment in both the cortex and medulla. Both cortical and
medullary Conray-induced decreases in NO release were
not reversed with SOD treatment, suggesting that oxygen-
derived free radicals did not contribute to the Conray-
induced decrease in cortical and medullary NO release
(Figs 4 and 5). Pretreatment of the animals with L-NAME
before Conray administration did further decrease medul-
JOURNAL OF VASCULAR SURGERY
August 2006386 Myers et allary, but not cortical, NO release. The L-NAME data
suggested that the NO synthesis inhibition was maximal in
the cortex after treatment of the Conray alone. L-arginine
pretreatment restored the cortical and medullary release of
NO back toward saline levels, but this did not reach statis-
tical significance (Figs 4, 5).
Conray treatment decreased cortical release of PGE2,
but medullary PGE2 was unchanged. Interestingly, SOD
treatment did not alter cortical PGE2 release but decreased
medullary PGE2 by 50% compared with Conray treatment
alone (see Figs 6 and 7). Treatment of the Conray groups
with L-NAME or L-arginine did not alter PGE2 release in
either the cortex or medulla (Fig 6 and 7). The release of
thromboxane B2 and 6-keto-PGF1 from the cortex and
medulla was not altered by any of the drug treatment
regimens (Fig 8 and 9).
The administration of Conray 400 did not alter cortical
or medullary content of iNOS, COX-2, PGE2 synthase, or
prostacyclin synthase (Fig 10). Conray treatment caused a
marked decrease in the creatinine clearance compared with
the saline treated group and with the baseline time zero
group before Conray 400 treatment (Fig 11).
Treatment of the Conray group with SOD or L-
Fig 1. The effect of Conray 400 on blood pressure (A) and heart
rate (B). The arterial blood pressure and heart rate was continu-
ously monitored at basal time zero and after 60 minutes after
administration of Conray 400. The Conray groups were treated
with either saline carrier, superoxide dismutase (C	 SOD, 10,000
U/kg), an oxygen-derived free radical scavenger; N-nitro-L-
arginine methyl ester hydrochloride (C	 L-NAME, 30 mg/kg), a
nitric oxide synthase; or L-Arginine (C 	 L-Arg, 400 mg/kg) a
nitric oxide precursor. Data are reported as mm Hg (A) and beats
per minute (B) and expressed as mean SEM (n 6). a, Indicates
significance at P  .05 compared with saline group; b, indicates
significance at P .05 compared with the Conray 400 group; and
d, indicates significance compared with the Conray 400 	 L-
arginine group at P  .05.arginine did not significantly alter creatinine clearance. Theaddition of L-NAME to Conray significantly decreased
creatinine clearance compared with both the saline group
and the group treated with Conray 400 alone (Fig 11).
DISCUSSION
The increasing number of diagnostic and endovascular
procedures requiring contrast media has been associated
with a parallel increase in the incidence of contrast media-
induced nephropathy. In fact contrast media-induced ne-
phropathy now accounts for up to 10% of acute renal failure
acquired in the hospital1,2,7,9,29 and contributes to in-
creased hospital length of stay, morbidity, mortality, and
acceleration toward end-stage renal disease.1,2,29 One of
the difficulties involved with preventing contrast media-
induced nephropathy is the lack of insight into the specific
mechanism or mechanisms of the contrast-induced renal
injury.Within the past 20 years, a large number of strategies
to prevent contrast media-induced nephropathy have been
tried, including a variety of intravenous fluid regimens,
osmotic and loop diuretics, dopamine, adenosine antago-
nists, agents with antioxidant properties, and hemofiltra-
tion. None of these prevention strategies have been shown
to ameliorate contrast media-induced nephropathy consis-
tently.1,3,5,29-35
One of the strategies to prevent contrast media-
induced nephropathy has been the use of the oxygen-
derived free radical scavenger N-acetylcysteine (NAC).34,35
Fig 2. The effect of Conray 400 on renal cortical blood flow.
Laser Doppler probes were placed 2 mm into the cortex and blood
flow was continuously monitored at basal time zero and after 60
minutes after administration of Conray 400. The Conray groups
were treated with saline carrier, Conray 400 (6 mls/kg), superox-
ide dismutase (SOD, 10,000 U/kg), an oxygen-derived free radi-
cal scavenger; N-nitro-L-arginine methyl ester hydrochloride (L-
NAME, 30 mg/kg), a nitric oxide synthase inhibitor; or
L-arginine (L-Arg, 400 mg/kg), a nitric oxide precursor. Data are
reported as percent change compared with baseline time zero
(mean SEM). a, indicates significance at P .05 compared with
the saline group; b, indicates significance at P .05 compared with
the Conray 400 group; c, indicates significance at P  .05 com-
pared with the Conray 400	 L-NAME group; d, indicates signif-
icance compared to the Conray 400 	 L-arginine group at P 
.05.NAC is an inexpensive water-soluble molecule that has
compared to the Conray 400 	 L-arginine group at P  0.05.
the saline group.
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to acetaminophen.36,37 The mechanism of NAC-related
renal protection has been attributed to a scavenging oxy-
gen-derived free radical, either directly or through increas-
ing intracellular glutathione concentration.36,37
Heyman et al38 showed in an experimental study with
rats that the renal protective effect of NAC may be partly
due to amelioration of renal vasoconstriction; however, the
biochemical mechanisms of this action were not deter-
mined. Several other authors have cast doubt on the benefit
of NAC in clinical trials, and several meta-analyses have
reached conflicting conclusions about the efficacy of NAC
to prevent contrast media-induced nephropathy.34,35 Our
data showed that addition of SOD, an inhibitor of super-
oxide radical production, to the Conray 400 treatment did
not prevent the Conray-induced fall in medullary and cor-
tical blood flow. Our data suggest that oxygen-derived free
radicals did not contribute to the contrast media-induced
nephropathy and, in fact, were required to maintain med-
ullary NO synthesis and blood flow.
Renal vasoconstriction has been hypothesized to be
one of the contributing factors to contrast media-induced
nephropathy.39 Both NO and vasodilator eicosanoids have
been shown to be endogenous mediators that contribute to
the maintenance of normal renal blood flow and function
under normal physiologic conditions.40-46 The loss of en-
dogenous renal NO synthesis has been suggested to con-
Fig 5. The effect of Conray 400 on renal medullary nitric oxide
(NO) release. Microdialysis probes were placed 4 mm into the
cortex, connected to a syringe pump and perfused in vivo at 3
L/min with lactated ringer’s solution. Dialysate fluid was col-
lected at basal time zero and after 60minutes after Conray or Saline
treatment. The Conray groups were treated with saline carrier,
superoxide dismutase (SOD, 10,000 U/kg), an oxygen-derived
free radical scavenger; N-nitro-L-arginine methyl ester hydro-
chloride (L-NAME, 30 mg/kg), a nitric oxide synthase inhibitor;
or L-arginine (L-Arg, 400 mg/kg) a NO precursor. The NO data
are expressed as percent change compared to baseline time zero
(mean SEM). a, Indicates significance at P .05 compared with
saline group; b, indicates significance at P .05 compared with the
Conray 400 group.Fig 3. The effect of Conray 400 on renal medullary blood flow.
Laser Doppler probes were placed 4 mm into the medulla and
blood flowwas continuously monitored at basal time zero and after
60 minutes after administration of Conray 400. The Conray
groups were treated with saline carrier, superoxide dismutase
(SOD, 10,000 U/kg), an oxygen-derived free radical scavenger;
N-nitro-L-arginine methyl ester hydrochloride (L-NAME, 30
mg/kg), a nitric oxide synthase inhibitor; or L-arginine (L-Arg,
400 mg/kg), a nitric oxide precursor. Data are reported as percent
change compared with baseline time zero (mean  SEM). a,
indicates significance at P  .05 compared with saline group; b,
indicates significance at P  .05 compared with the Conray 400
group; c, indicates significance at P  .05 compared with the
Conray 400 	 L-NAME group; and d, indicates significanceFig 4. The effect of Conray 400 on renal cortical nitric oxide
(NO) release. Microdialysis probes were placed 2 mm into the
cortex, connected to a syringe pump, and perfused in vivo at 3
L/min with lactated Ringer’s solution. Dialysate fluid was col-
lected at basal time zero and after 60minutes after Conray or saline
treatment. The Conray groups were treated with saline carrier,
superoxide dismutase (SOD, 10,000 U/kg), an oxygen-derived
free radical scavenger; N-nitro-L-arginine methyl ester hydro-
chloride (L-NAME, 30 mg/kg), a nitric oxide synthase inhibitor;
or L-arginine (L-Arg, 400 mg/kg) a NO precursor. The NO data
is expressed as percent change compared with baseline time zero
(mean SEM). a, indicates significance at P .05 compared withtribute to renal vasoconstriction after renal ischemia-reper-
compared with the saline group.
group.
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vasodilator eicosanoids PGE2 and PGI2 has been associated
with renal vasoconstriction after several injuries, including
renal and intestinal ischemia-reperfusion injury.17,43,49-52
Several studies have investigated the role of either eico-
sanoids or NO as mediators in contrast media-induced
renal vasoconstriction. The data from these studies strongly
suggested that the contrast-induced renal vasoconstriction
was partly due to the loss of endogenous renal eicosanoids
or NO. A more recent study by Agnon et al11 used simul-
taneous pharmacologic blockade of both NOS (L-NAME)
and COX (indomethacin) to indirectly examine the role for
both NO and eicosanoids in contrast media-induced renal
vasoconstriction. The results of this study showed that the
combined administration of L-NAME and indomethacin,
given before treatment with radiocontrast media, decreased
Fig 8. The effect of Conray 400 on renal cortical (A) and med-
ullary (B) 6-keto-PGF1 (PGI2 metabolite) release. Microdialysis
probes were placed 2 mm into the cortex and 4 mm into the
medulla, connected to a syringe pump and perfused in vivo at 3
L/min with lactated ringer’s solution. Dialysate fluid was col-
lected at basal time zero and after 60minutes after Conray or Saline
treatment. The Conray groups were treated with saline carrier,
superoxide dismutase (SOD, 10,000 U/kg), an oxygen-derived
free radical scavenger; N-nitro-L-arginine methyl ester hydro-
chloride (L-NAME, 30 mg/kg), a nitric oxide synthase inhibitor;
or L-arginine (L-Arg, 400 mg/kg) a nitric oxide precursor. The
6-keto-PGF1 data are expressed as percent change compared with
baseline time zero (mean  SEM). No significance changes were
seen.Fig 6. The effect of Conray 400 on renal cortical prostaglandin
E2 (PGE2) release. Microdialysis probes were placed 2mm into the
cortex, connected to a syringe pump and perfused in vivo at 3
L/min with lactated Ringer’s solution. Dialysate fluid was col-
lected at basal time zero and after 60minutes after Conray or saline
treatment. The Conray groups were treated with saline carrier,
superoxide dismutase (SOD, 10,000 U/kg), an oxygen-derived
free radical scavenger; N-nitro-L-arginine methyl ester hydro-
chloride (L-NAME, 30 mg/kg), a nitric oxide synthase inhibitor;
or L-arginine (L-Arg, 400 mg/kg) a nitric oxide precursor. The
PGE2 data are expressed as percent change compared with baseline
time zero (mean  SEM). a, Indicates significance at P  .05Fig 7. The effect of Conray 400 on renal medullary prostaglandin
E2 (PGE2) release. Microdialysis probes were placed 4mm into the
medulla, connected to a syringe pump and perfused in vivo at 3
L/min with lactated Ringer’s solution. Dialysate fluid was col-
lected at basal time zero and after 60minutes after Conray or saline
treatment. The Conray groups were treated with saline carrier,
superoxide dismutase (SOD, 10,000 U/kg), an oxygen-derived
free radical scavenger; N-nitro-L-arginine methyl ester hydro-
chloride (L-NAME, 30 mg/kg), a nitric oxide synthase inhibitor;
or L-arginine (L-Arg, 400 mg/kg) a nitric oxide precursor. The
PGE2 data are expressed as picograms per milliliter (mean 
SEM). a, Indicates significance at P .05 compared with the salinemedullary blood flow by 88% of baseline.11 Although this
units  SEM (N8).
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by use of inhibitors of NOS and COX, it was the first study
to suggest that both vasodilator eicosanoids and NO have
an important protective role in the renal response to con-
trast media.11
Our laboratory has recently combined the techniques
of in vivo microdialysis and laser Doppler blood flow to
investigate for the first time, to our knowledge, real-time
changes in renal cortical andmedullary blood flow, andNO
and PGE2 synthesis after contrast media administration.
Conray 400 caused a marked decrease in cortical and
medullary blood flow with a concomitant decrease in en-
dogenous cortical NO synthesis. The addition of L-NAME
to the Conray 400 treatment further decreased cortical and
medullary blood flow and NO synthesis, which were re-
stored toward control by L-arginine treatment. Neither
Fig 9. The effect of Conray 400 on renal cortical (A) and med-
ullary (B) thromboxane B2 (thromboxane A2 metabolite) release.
Microdialysis probes were placed 2 mm into the cortex and 4 mm
into themedulla, connected to a syringe pump and perfused in vivo
at 3 L/min with lactated Ringer’s solution. Dialysate fluid was
collected at basal time zero and after 60 minutes after Conray or
saline treatment. The Conray groups were treated with saline
carrier, superoxide dismutase (SOD, 10,000 U/kg), an oxygen-
derived free radical scavenger; N-nitro-L-arginine methyl ester
hydrochloride (L-NAME, 30 mg/kg), a nitric oxide synthase
inhibitor; or L-arginine (L-Arg, 400 mg/kg) a nitric oxide precur-
sor. The thromboxane B2 data is expressed as (mean  SEM). No
significance changes were seen.L-NAME nor L-arginine treatment, when added to theFig 10. The effect of Conray 400 on renal cortical and medullary
inducible nitric oxide synthase (iNOS) and cyclooxygenase 2
(COX-2) (A) and prostaglandin E2 (E2) synthase and prostacyclin
synthase (PS) (B) content. Protein from renal cortex and medulla
was prepared from animals from the Saline and Conray 400 and
subjected to Western blot analysis to identify content of iNOS,
COX-2, PGE2 synthase, and prostacyclin synthase. The blots were
analyzed by densitometry. Data are expressed as densitometryFig 11. The effect of Conray 400 on creatinine clearance (CrCl).
Serum and urine were collected from separate groups of animals to
measure serum creatinine, urine creatinine, and urine volume to
calculate creatinine clearance. The serum and urine was collected at
basal time zero and after 60 minutes after Conray 400 treatment
and compared with saline control. Conray groups were treated
with superoxide dismutase (SOD, 10,000 U/kg), an oxygen-
derived free radical scavenger; N-nitro-L-arginine methyl ester
hydrochloride (L-NAME, 30 mg/kg), a nitric oxide synthase
inhibitor; or L-arginine (L-Arg, 400 mg/kg) a nitric oxide precur-
sor. Data are reported as milliliters per minute (mean SEM) (n
6). a, Indicates significance at P.05 compared with saline group;
b, Indicates significance at P .05 compared with saline group and
the group treated only with Conray 400.
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lease. These findings suggest that the Conray 400-induced
decrease in cortical and medullary blood flow was partly
mediated by the loss of endogenous cortical and medullary
NO and PGE2 synthesis. SOD added before the Conray
400 treatment did not alter cortical or medullary blood
flow, suggesting that oxygen-derived free radicals were not
important factors in mediating the Conray 400-induced
decrease in cortical and medullary blood flow.
Our renal function data support the previous literature
that suggests that contrast media-induced nephropathy is a
complex disease, is poorly understood, and most likely due
to etiologies in addition to renal cortical and medullary
vasoconstriction. Conray 400 dramatically decreased creat-
inine clearance, which was not reversed by either SOD or
L-arginine treatment (Fig 11). The further decrease in
creatinine clearance by addition of L-NAME to the Conray
400 treatment suggests that loss of endogenous renal NO
does partly contribute to decreased renal function (Fig 11).
It is obvious, however, that the profound decrease in cre-
atinine clearance after Conray 400 treatment is due to other
mediators besides NO.
The Western blot data showed that Conray 400 treat-
ment did not significantly alter cortical or medullary con-
tent of iNOS, COX-2, PGE2 synthase, or prostacyclin
synthase. These findings suggest that the contrast-induced
decreases in cortical and medullary NO synthesis and cor-
tical PGE2 synthesis were due to a decrease in the activity of
NOS and COX and not due to a downregulation of these
enzymes. These results make sense, because the contrast-
induced injury is an acute injury and most likely represents
what occurs in the clinical setting. Changes in COX or
iNOS content would most likely require a long-term ad-
ministration of the contrast agent, which would not mimic
the clinical use of these agents.
Several important limitations should be noted with the
present study. Our study was limited to examining the
effect of Conray 400 on renal cortical and medullary NO
and eicosanoid synthesis. Conray 400 is a hyperosmolar
contrast agent, a class that would be used in a small per-
centage of patients treated with contrast agents. This is the
classic contrast agent studied in the literature, however, and
its use is important for two reasons: (1) it allows us to
compare our findings with those previously published, and
(2) it is important to use the most potentially damaging
contrast agent used clinically so we can begin to identify the
specific mechanism of the intrarenal injury. One can then
intelligently begin to compare the other classes of contrast
agents to determine if their respective proposed advantages
preserve renal blood flow and function.
Another limitation of our study was that we did not
examine the effect of Conray 400 on other important
vasoactive mediators that contribute to either maintaining
or decreasing renal blood flow and function. Previous
experimental work has identified a large number of poten-
tial mediators, including endothelin, hypoxia, and local
acidosis, whichmay contribute to the decreased renal blood
flow and function after radiocontrast treatment.Future studies utilizing our unique combination of in
vivo physiologic techniques will be needed to further iden-
tify the vasoactive mediators that contribute to the con-
trast-induced renal injury. One would like a full under-
standing of all of the factors involved with contrast-induced
renal injury to help identify treatment strategies to lessen or
prevent this serious clinical problem.
CONCLUSION
This study suggests that clinically relevant cortical and
medullary vasodilators (NO and vasodilator prostanoids)
are required to maintain microvascular renal cortical and
medullary blood flow. The results of this study suggest that
endogenous cortical and medullary NO have an important
protective role in preventing vasoconstriction at the local
level after radiocontrast administration. Finding strategies
to maintain endogenous cortical and medullary NO and
PGE2 synthesis, both potent endogenous renal vasodila-
tors, may help to contribute to the development of treat-
ment strategies to prevent renal vasoconstriction and injury
following radiocontrast administration.
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